Media Advisory - Canadian science equipment flying to the International Space Station: technical briefing
LONGUEUIL, QC, April 9, 2019 /CNW Telbec/ - On Wednesday, April 10, during NASA's technical briefing, Dr. Richard L. Hughson will discuss Vascular Aging, a Canadian experiment that will examine cardiovascular health on the International Space Station (ISS). Equipment for this Canadian study will be on board Northrop Grumman's Cygnus resupply ship, scheduled to launch to the ISS on April 17.
Media representatives are invited to watch the briefing live on the CSA's YouTube channel.
To participate in the teleconference, media must contact Gina Anderson at 202-358-1160 or [email protected] by 1:00 p.m. ET Tuesday, April 9, for dial-in information.
Date:
Wednesday, April 10, 2019
Time:
1:00 p.m. ET
What:
Technical briefing on the science and technology on the next Northrop Grumman resupply mission to the ISS
Who:
Richard L. Hughson, Schlegel Research Chair in Vascular Aging and Brain Health and Senior Director of Research at the University of Waterloo Research Institute for Aging
On June 29, the "Gather Great Wisdom to Shape the Future of Intelligent Manufacturing?Special Exhibition on Design Intelligence and High Quality Development", hosted by the China Academy of Art (CAA), opened at the National Museum of China in...
Intermap Technologies ("Intermap" or the "Company"), a global leader in 3D geospatial products and intelligence solutions, announces a new financing. The Company is offering up to a maximum of 4,300,000 Class "A" common shares of the Company...
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...
Enterprises in Asia Pacific are moving toward software-defined networking (SDN) to make communication more secure and resilient and speed up business decision-making, according to a new research report published today by Information Services Group...
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...
